Immunwork Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$24M
- Investors
-
6
Immunwork General Information
Description
Operator of a drug development platform intended to develop long-acting drugs for endocrine diseases and antibody-based drugs for cancer treatment. The company offers a fatty acid bundle platform for developing long-acting drug candidates and antibody-drug conjugate and antibody-radionuclide conjugate platforms for developing drugs for endocrine diseases and cancers, enabling pharmaceutical and biotechnology companies to develop drugs with extended activity and targeted delivery.
Contact Information
Website
www.immunwork.comCorporate Office
- Number 99, Lane 130, Sector 1, Academia Road
- C520, Building C, Nangang District
- Taipei City, 115-17
- Taiwan
Corporate Office
- Number 99, Lane 130, Sector 1, Academia Road
- C520, Building C, Nangang District
- Taipei City, 115-17
- Taiwan
Immunwork Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 08-Mar-2022 | $24M | Completed | Generating Revenue |
Immunwork Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immunwork Patents
Immunwork Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026536412-A | A pharmaceutical formulation of a glucagon-like peptide-1 receptor agonist peptide for sublingual administration. | Pending | 29-Jan-2024 | ||
| AU-2025214636-A1 | Pharmaceutical formulation of glucagon-like peptide -1 receptor agonist peptide for sublingual delivery | Pending | 29-Jan-2024 | ||
| US-20250241994-A1 | Pharmaceutical formulation of glucagon-like peptide -1 receptor agonist peptide for sublingual delivery | Pending | 29-Jan-2024 | ||
| WO-2025161997-A1 | Pharmaceutical formulation of glucagon-like peptide -1 receptor agonist peptide for sublingual delivery | Pending | 29-Jan-2024 | ||
| US-20240342298-A1 | Methods of treating tumors by using molecular construct | Pending | 13-Apr-2023 | A61K47/6803 |
Immunwork Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immunwork Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Center Laboratories | Accelerator/Incubator | Minority | ||
| Fubon Financial Holding Venture Capital | Venture Capital | Minority | ||
| Gen Kai Enterprise | Corporation | Minority | ||
| Maxpro Ventures | Venture Capital | Minority | ||
| Taya Group | Corporation | Minority |
Immunwork FAQs
-
When was Immunwork founded?
Immunwork was founded in 2014.
-
Where is Immunwork headquartered?
Immunwork is headquartered in Taipei City, Taiwan.
-
What is the size of Immunwork?
Immunwork has 20 total employees.
-
What industry is Immunwork in?
Immunwork’s primary industry is Drug Discovery.
-
Is Immunwork a private or public company?
Immunwork is a Private company.
-
What is Immunwork’s current revenue?
The current revenue for Immunwork is .
-
How much funding has Immunwork raised over time?
Immunwork has raised $24M.
-
Who are Immunwork’s investors?
Center Laboratories, Fubon Financial Holding Venture Capital, Gen Kai Enterprise, Maxpro Ventures, and Taya Group are 5 of 6 investors who have invested in Immunwork.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
